Investigational drug · Phase 3
HS-20117
Also called: PM1080
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Squamous Non-Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "HS-20117"
First trial start
2024
May 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-20117", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Squamous Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-20117" as an intervention, largest first.
- A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerPivotal-lookingRecruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06417008 · 1,080 participants (planned) · Start May 28, 2024 · Primary completion Jun 1, 2026
Drug: HS-20117; Aumolertinib · For: Non-Squamous Non-Small Cell Lung Cancer
Sites: Tianjin, China; Hangzhou, China
Hansoh BioMedical R&D CompanyIndustry
NCT06621563 · 780 participants (planned) · Start Dec 14, 2024 · Primary completion Mar 30, 2026
Drug: HS-20117 combined HS-20093; HS-20117 combined Platinum-containing chemotherapy and 4 more · For: Solid Tumors; Non-Small Cell Lung Cancer; Colorectal Cancer
Sites: Tianjin, China
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06963502 · 762 participants (planned) · Start May 30, 2025 · Primary completion Dec 31, 2028
Drug: HS-10370; HS-20117 and 6 more · For: Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer
Sites: Hangzhou, China; Shanghai, China
- A Phase Ib Study of HS-10504 Combined Therapy in NSCLCNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07414953 · 400 participants (planned) · Start Mar 30, 2026 · Primary completion Apr 30, 2027
Drug: HS-10504; SHR-A2009 and 4 more · For: Lung Cancer
Hansoh BioMedical R&D CompanyIndustry
NCT05940116 · 322 participants (planned) · Start Jul 20, 2023 · Primary completion Jul 30, 2025
Drug: HS-20117 · For: Non-Small Cell Lung Cancer; Solid Tumor
Sites: Tianjin, China
Hansoh BioMedical R&D CompanyIndustry
NCT07775703 · 60 participants (planned) · Start Nov 13, 2025 · Primary completion Dec 30, 2027
Drug: HS-20117-2 Injection · For: Advanced Solid Tumors
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Squamous Non-Small Cell Lung Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- AumolertinibSHR-A2009, HS-10296Phase 37 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Advanced Solid Tumors
- EU-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- US-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.